A Comparison of Cryotherapy and Imiquimod for Treatment of Actinic Keratoses: Lesion Clearance, Safety, and Skin Quality Outcomes
Peter Foley, Kate Merlin, Simon Cumming, Jan Campbell, Rohan Crouch, Shannon Harrison, Jennifer Cahill
JOURNAL OF DRUGS IN DERMATOLOGY | JOURNAL OF DRUGS IN DERMATOLOGY | Published : 2011
BACKGROUND: There is limited direct comparative data on imiquimod versus cryotherapy to treat actinic keratoses. OBJECTIVE: Compare lesion response through 12 months post-initial treatment. METHODS: Patients with ≥ 10 lesions on the face or scalp were randomized to cryotherapy (up to 10 lesions per session, up to 4 sessions, every 3 months) or imiquimod (3-times-per-week for 3-4 weeks, up to 2 courses) with repeat treatment depending on response. RESULTS: In 36 patients assigned to cryotherapy and 35 to imiquimod, lesion complete response rates were 85.0 percent (306/360) and 66.9 percent (234/350) for cryotherapy and imiquimod, respectively (P<0.0002). For completely cleared lesions, global..View full abstract
This study was supported by an unrestricted educational grant and a gift of imiquimod 5% cream by 3M Pharmaceuticals. Peter Foley MD has been a clinical investigator and a speaker for 3M Pharmaceuticals. The authors would like to acknowledge the patients who participated in the study, and L. Charles and T Meng for editorial assistance.Peter Foley MD has been a clinical investigator for studies sponsored by Photo Cure ASA, Galderma R&D, QLT Inc., Peplin Ltd., and 3M Pharmaceuticals, has been a scientific meeting speaker for Photo Cure ASA, Galderma R&D, iNova, and 3M Pharmaceuticals, and has been a medical advisory board member for Galderma Australia. The other authors have no conflicts of interest to disclose. 3M Pharmaceuticals provided an unrestricted educational grant and a gift of imiquimod 5% cream.